55 related articles for article (PubMed ID: 38576619)
21. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
[TBL] [Abstract][Full Text] [Related]
22. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Xu J; Kato K; Raymond E; Hubner RA; Shu Y; Pan Y; Park SR; Ping L; Jiang Y; Zhang J; Wu X; Yao Y; Shen L; Kojima T; Gotovkin E; Ishihara R; Wyrwicz L; Van Cutsem E; Jimenez-Fonseca P; Lin CY; Wang L; Shi J; Li L; Yoon HH
Lancet Oncol; 2023 May; 24(5):483-495. PubMed ID: 37080222
[TBL] [Abstract][Full Text] [Related]
23. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
[TBL] [Abstract][Full Text] [Related]
24. The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab.
Liu J; Gao D; Li J; Hu G; Liu J; Liu D
Onco Targets Ther; 2022; 15():1161-1170. PubMed ID: 36238132
[TBL] [Abstract][Full Text] [Related]
25. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Obermannová R; Alsina M; Cervantes A; Leong T; Lordick F; Nilsson M; van Grieken NCT; Vogel A; Smyth EC;
Ann Oncol; 2022 Oct; 33(10):992-1004. PubMed ID: 35914638
[No Abstract] [Full Text] [Related]
26. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
28. Models for Predicting Early Death in Patients With Stage IV Esophageal Cancer: A Surveillance, Epidemiology, and End Results-Based Cohort Study.
Shi M; Zhai GQ
Cancer Control; 2022; 29():10732748211072976. PubMed ID: 35037487
[TBL] [Abstract][Full Text] [Related]
29. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
31. Metastasis Patterns and Prognosis of Elderly Patients With Esophageal Adenocarcinoma in Stage IVB: A Population-Based Study.
Qiu G; Zhang H; Wang F; Zheng Y; Wang Z; Wang Y
Front Oncol; 2021; 11():625720. PubMed ID: 34123784
[TBL] [Abstract][Full Text] [Related]
32. Palliative Radiotherapy Versus Esophageal Stent Placement in the Management of Patients With Metastatic Esophageal Cancer.
Martin EJ; Bruggeman AR; Nalawade VV; Sarkar RR; Qiao EM; Rose BS; Murphy JD
J Natl Compr Canc Netw; 2020 May; 18(5):569-574. PubMed ID: 32380466
[TBL] [Abstract][Full Text] [Related]
33. M2 polarization of tumor-associated macrophages is dependent on integrin β3 via peroxisome proliferator-activated receptor-γ up-regulation in breast cancer.
Shu Y; Qin M; Song Y; Tang Q; Huang Y; Shen P; Lu Y
Immunology; 2020 Aug; 160(4):345-356. PubMed ID: 32311768
[TBL] [Abstract][Full Text] [Related]
34. Systematic cancer-testis gene expression analysis identified CDCA5 as a potential therapeutic target in esophageal squamous cell carcinoma.
Xu J; Zhu C; Yu Y; Wu W; Cao J; Li Z; Dai J; Wang C; Tang Y; Zhu Q; Wang J; Wen W; Xue L; Zhen F; Liu J; Huang C; Zhao F; Zhou Y; He Z; Pan X; Wei H; Zhu Y; He Y; Que J; Luo J; Chen L; Wang W
EBioMedicine; 2019 Aug; 46():54-65. PubMed ID: 31324603
[TBL] [Abstract][Full Text] [Related]
35. Inflammation and Cancer: Triggers, Mechanisms, and Consequences.
Greten FR; Grivennikov SI
Immunity; 2019 Jul; 51(1):27-41. PubMed ID: 31315034
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of combined pretreatment body mass index (BMI) and BMI loss in patients with esophageal cancer.
Gu WS; Fang WZ; Liu CY; Pan KY; Ding R; Li XH; Duan CH
Cancer Manag Res; 2019; 11():3029-3041. PubMed ID: 31114349
[No Abstract] [Full Text] [Related]
37. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Distant Metastasis Between Histological Types in Esophageal Cancer.
Wu SG; Zhang WW; Sun JY; Li FY; Lin Q; He ZY
Front Oncol; 2018; 8():302. PubMed ID: 30135855
[No Abstract] [Full Text] [Related]
39. Lymphocyte-to-monocyte ratio in esophageal squamous cell carcinoma prognosis.
Hu G; Liu G; Ma JY; Hu RJ
Clin Chim Acta; 2018 Nov; 486():44-48. PubMed ID: 30028962
[TBL] [Abstract][Full Text] [Related]
40. A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma.
Hiramoto S; Kato K; Shoji H; Okita N; Takashima A; Honma Y; Iwasa S; Hamaguchi T; Yamada Y; Shimada Y; Boku N
Int J Clin Oncol; 2018 Jun; 23(3):466-472. PubMed ID: 29353337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
